•Diplomate of the American Board of Toxicology
•Over twenty years of professional experience in medicine, biomaterials, biocompatibility, immunology, including pharmacology and toxicology with more than 20 peer-reviewed publications;
•Six years of the FDA experience including two years Pharmacology/Toxicology reviewer in CDER and four years immunologist/consulting reviewer/principle investigator in CDRH involved in products approval processes;
•Broad array of knowledge in pharmacology/toxicology, biomarkers, medicine, immunology, tissue engineering, biomaterials, stem cells, molecular-cell biology and animal modeling in range from mechanistic approaches, preclinical safety assessment to a variety of clinical applications;
•Thorough knowledge and techniques in basic biology, medical and regulatory sciences/standard/guidance
•Developed and conducted purpose-specific research protocols to address specific safety concerns for industries in the enhancement of their approvability.
|
|
2013, Diplomate of the American Board of Toxicology
2010 – Present, Immunologist, work topics: consulting review and regulatory research; as a consulting reviewer provide expert opinions and recommendations into requested review documents from other reviewers, especially in products associated immunotoxicity in preclinical risk assessment, offer purpose-specific experimental protocols to help sponsor in addressing the safety concerns, and involved in the regulatory approval process. As a principal investigator also focus on non-animal based clinically relevant biomarker identification and development for preclinical risk assessment and clinical risk management; collaboration with academic in computational quantitative chemical structure-biological activity relationship in CDRH/FDA;
2011 Critical Path Initiative granted to identify and develop biomarkers for addressing regulatory specific safety concerns, medical device associated immunotoxicity and overcoming the limitations of animal based testing methods;
2008 – 2010, CDER/FDA, Pharmacology/Toxicology Reviewer, work topics: review the drugs/immunosuppressants included small molecules and monoclonal antibodies in renal transplantation and its risk management.
Work topics: consulting review and regulatory research; as a consulting reviewer provide expert opinions and recommendations into requested review documents from other reviewers, especially in products associated immunotoxicity in preclinical risk assessment, offer purpose-specific experimental protocols to help sponsors in addressing the safety concerns, and involved in the regulatory approval process. As a principal investigator focus on non-animal based human biomarker identification and development for preclinical risk assessment and clinical risk management; collaboration with academic in computational quantitative chemical structure-biological activity relationship in CDRH/FDA;
•2011 Critical Path Initiative granted to identify and develop biomarkers for addressing regulatory specific safety concerns, medical device associated immunotoxicity and overcoming the limitation of animal based testing methods.
As a Pharmacology/Toxicology Reviewer, work topics: review the drugs/immunosuppressants included small molecules and monoclonal antibodies in renal transplantation and its risk management;
•Members of the Society of Toxicology (external); members of Biocompatibility Standards Technical Group.
Focused on clinical pharmacology, mechanistic and pharmacological based drug development
work topics: pharmacogenomics based cytochrome P450 regulation and chemical induced liver toxicity/Pharmacology and Toxicology, and new drug discovery and development, one new molecule entity was patented.
pharmacogenomics based cytochrome P450 regulation and chemical induced liver toxicity/Pharmacology and Toxicology
Stem cells induced bone tissue engineering
metallic partials induced immunotoxicity in laboratory animals
Biomaterials/metallic and polymer partials induced immune reactions in laboratory animals and primary macrophages
Continuing Education
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Companies Worked For:
School Attended
Job Titles Held:
Degrees
© 2021, Bold Limited. All rights reserved.